



Final Appraisal Recommendation

Capecitabine (Xeloda[®])

Submission by:
Roche Products Ltd

Advice No: 0511 – April 2011

Recommendation of AWMSG

Capecitabine (Xeloda[®]) in combination with oxaliplatin is recommended as an option for use within NHS Wales for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer.

Capecitabine (Xeloda[®]) is not suitable for shared care within NHS Wales for the above indication.

Additional note:

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report, the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion, lay/patient/carer perspective and discussions at AWMSG.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: